U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT06832865) titled 'ELISA in Relapsed/Refractory MM' on Feb. 13.
Brief Summary: This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior lines of therapy and who have had previous treatment with both immunomodulatory drugs (IMiDs) and a proteasome inhibitor (PI). The subcutaneous injection method of isatuximab administration, including the device used to administer isatuximab, is investigational.
Study Start Date: Aug. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Relapsed Refractory Multiple My...